{"nctId":"NCT00942604","briefTitle":"A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","startDateStruct":{"date":"2009-07"},"conditions":["Actinic Keratoses"],"count":203,"armGroups":[{"label":"PEP005 (ingenol mebutate) Gel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: PEP005 (ingenol mebutate) Gel"]},{"label":"Vehicle gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle gel"]}],"interventions":[{"name":"PEP005 (ingenol mebutate) Gel","otherNames":[]},{"name":"Vehicle gel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be male or female and at least 18 years of age.\n* Female patients must be of:\n* Non-childbearing potential;\n* Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception.\n* 4 to 8 AK lesions on non-head locations.\n\nExclusion Criteria:\n\n* Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.\n* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks.\n* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions","description":"Proportion of Patients with Complete Clearance of the treatment field defined as no clinically visible Actinic Keratoses (AK) lesions in the selected treatment area","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Partial Clearance of Actinic Keratoses (AK) Lesions","description":"Proportion of patients with Partial Clearance defined as â‰¥ 75 % reduction in the number of Actinic Keratoses (AK) lesions identified at baseline in the treatment area","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":100},"commonTop":["Application site pruritus","Application site irritation"]}}}